Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Processa Pharmaceuticals ( (PCSA) ) has issued an announcement.
On August 25, 2025, Processa Pharmaceuticals, Inc. announced a change in the location for its 2025 Special Meeting of Stockholders. The meeting was moved from Vero Beach, FL to Pasadena, CA, reflecting a logistical adjustment by the company’s board of directors.
The most recent analyst rating on (PCSA) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Average Trading Volume: 19,462,291
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.98M
Learn more about PCSA stock on TipRanks’ Stock Analysis page.